Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference
New York, Jan 12, 2026, 14:41 EST — Regular session Apellis Pharmaceuticals shares dropped almost 15% Monday following the release of preliminary 2025 U.S. sales numbers ahead of its J.P. Morgan Healthcare Conference update. The move put the stock in focus as biotech firms roll out early guidance for the year. Timing is key. The J.P. Morgan meeting tends to…